Thu, Jul 31, 2014, 8:29 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Omeros Corporation (OMER) Message Board

  • dooper55 dooper55 Nov 5, 2012 7:51 AM Flag

    Omeros' Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial

    -- Submission of New Drug Application Planned for First Half of 2013--

    -- Company to Host Conference Call Today at 9:00 a.m. EST--

    SEATTLE, Nov. 5, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery. In this second Phase 3 clinical trial comparing OMS302 to placebo, OMS302 met its co-primary endpoints by demonstrating statistically significant (p

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • doop - I have never seen a Phase III announcement ignored like this before. No doubt, there was not much drama involved - based on the first Phase III it was pretty clear the results would be positive, but absolutely no market reaction is a little scary? The conference call was well-attended by the analysts, who I assume will follow-up with some upgrades and/or price target adjustments, but this company is just not on any biotech investors/traders radar. One thing that I noticed on the call that could mute the analyst response is the company is still wishy-washy on whether they will partner the drug, at all. My sense is that if the OMS103HP results are solid, they will try to partner that and use the up-front money from that partnership to fund the building of a marketing platform for OMS302 - the eye surgeon market has to be easier to target/market to than the orthopedic surgeons? Oh well, I guess we'll have to wait on this one - the value is definitely there, but the market may not notice until a firm marketing plan is in place?

 
OMER
13.61-0.38(-2.72%)Jul 31 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
El Pollo Loco Holdings, Inc.
NasdaqGSThu, Jul 31, 2014 4:00 PM EDT
GoPro, Inc.
NasdaqGSThu, Jul 31, 2014 4:00 PM EDT